At a Glance
- Companies: Sanofi; Earendil Labs (Helixon Therapeutics affiliate)
- Location: Paris, France (Sanofi); Wilmington, Delaware, USA (Earendil)
- Deal value: $160m upfront/near‑term; up to $2.56bn total milestones plus low double‑digit royalties
- Focus area: AI‑powered discovery of bispecific antibodies for autoimmune/inflammatory diseases
- Next steps: Nominate and advance multiple bispecific candidates; Sanofi leads development and global commercialisation
What happened?
Sanofi has expanded its collaboration with AI biotech Earendil Labs to apply the latter’s discovery platform to multiple autoimmune and inflammatory disease programmes, focusing on next‑generation bispecific antibodies. Earendil receives up to $160 million in upfront and near‑term payments tied to early milestones, with the total deal value reaching up to $2.56 billion including development, regulatory and commercial milestones, plus tiered royalties on net sales up to low double‑digit percentages.
Why does it matter?
This second major pact between the partners—following a prior $1.8 billion deal for specific bispecifics—highlights Sanofi’s deepening commitment to AI‑driven biologics discovery in immunology, an area where bispecifics offer potential for superior efficacy over monospecifics by simultaneously targeting cytokines or cell types. Autoimmune diseases burden patients and healthcare systems with lifelong management and incomplete responses to current therapies, making efficient candidate generation critical ahead of competitive launches.
Who’s behind it?
Earendil Labs is a US‑based AI biotech specialising in predictive protein modelling and high‑throughput validation to design next‑generation biologics like bispecific antibodies. Sanofi, a global pharma leader with established immunology franchises, is leveraging such partnerships to bolster its early pipeline through external innovation.
How was it achieved?
The agreement grants Sanofi exclusive worldwide rights to bispecific candidates discovered using Earendil’s platform, which integrates AI sequence generation, property prediction and experimental optimisation for autoimmune targets. Sanofi handles all downstream development and commercialisation, while Earendil provides discovery support and receives milestone payments at key value inflection points.
What’s next?
The collaboration aims to rapidly nominate optimised bispecific candidates for preclinical advancement, with early data potentially feeding into Sanofi’s phase 1 pipeline and informing programme expansion. Subject to closing conditions, this positions both companies to accelerate transformative autoimmune therapies amid rising competition.
What are people saying?
Earendil CEO Jian Peng stated the partnership enables broader target application of its platform, combining “advanced predictive protein modeling with high‑throughput experimental validation” for efficient bispecific optimisation. Earendil President/Co‑CEO Zhenping Zhu emphasised addressing autoimmune burdens through Sanofi’s clinical and commercial expertise to deliver “potentially transformative medicines”.